Through a grant funded by MSU Gran Fondo donations, researchers will study two compounds that could improve treatment for melanoma. The team believes a compound they developed and a second one already approved by the FDA could increase the number of melanoma patients who respond well to a therapeutic called immune checkpoint inhibitors and prevent them from developing resistance to the treatment.
Colorectal cancer (CRC) is the third most common cancer type diagnosed in the United States in both men and women. The American Cancer Society estimates there will be nearly 150,000 new cases in 2021 and over 50,000 deaths. But CRC is preventable and very treatable if caught early. “Disparities in CRC screening have persisted in the African American community, but we have the tools to do something about it. If Black Lives Matter, then Black health should matter too,” Todd Lucas.
Thomas O’Halloran’s recent appointment as a Michigan State University Foundation Professor of Microbiology & Molecular Genetics and Chemistry completes a circle that began when he was a graduate student at Columbia University.
That’s when he became aware of pioneering work by MSU biophysicist Barnett Rosenberg, whose research in the 1970s led to the development of two transformative cancer-fighting drugs, cisplatin and carboplatin.